{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T21:54:54Z","timestamp":1783029294715,"version":"3.54.6"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,6]]},"DOI":"10.7759\/cureus.35814","type":"journal-article","created":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T11:59:50Z","timestamp":1678103990000},"source":"Crossref","is-referenced-by-count":6,"title":["Successful Treatment of Mucormycosis Caused by Rhizopus arrhizus With Amphotericin B and Itraconazole"],"prefix":"10.7759","author":[{"given":"Chen Yi","family":"Cham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuradha","family":"P. Radhakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chee Yik","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3109\/13693786.2012.669502","article-title":"Risk factors for mortality in patients with mucormycosis","volume":"50","author":"Spellberg B","year":"2012","unstructured":"Spellberg B, Kontoyiannis DP, Fredricks D, et al.. Risk factors for mortality in patients with mucormycosis. Med Mycol. 2012, 50:611-8. 10.3109\/13693786.2012.669502","journal-title":"Med Mycol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir866","article-title":"Epidemiology and clinical manifestations of mucormycosis","volume":"54","author":"Petrikkos G","year":"2012","unstructured":"Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis. 2012, 54:S23-34. 10.1093\/cid\/cir866","journal-title":"Clin Infect Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-017-1042-z","article-title":"Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients","volume":"45","author":"Bellmann R","year":"2017","unstructured":"Bellmann R, Smuszkiewicz P. Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients. Infection. 2017, 45:737-79. 10.1007\/s15010-017-1042-z","journal-title":"Infection"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2009.02972.x","article-title":"The ecology of the Zygomycetes and its impact on environmental exposure","volume":"15 Suppl 5","author":"Richardson M","year":"2009","unstructured":"Richardson M. The ecology of the Zygomycetes and its impact on environmental exposure. Clin Microbiol Infect. 2009, 15 Suppl 5:2-9. 10.1111\/j.1469-0691.2009.02972.x","journal-title":"Clin Microbiol Infect"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1177\/20101058221074112","article-title":"Rhino-orbital Mucormycosis in a COVID-19 Patient: The First Case in Malaysia","volume":"31","author":"Chang CY","year":"2022","unstructured":"Chang CY, Gan YL, Zamri FI, P. Radhakrishnan A. Rhino-orbital Mucormycosis in a COVID-19 Patient: The First Case in Malaysia. 2022, 31:20101058221074112. 10.1177\/20101058221074112"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0b013e3283165fd1","article-title":"Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment","volume":"21","author":"Ibrahim AS","year":"2008","unstructured":"Ibrahim AS, Spellberg B, Edwards J Jr. Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment. Curr Opin Infect Dis. 2008, 21:620-5. 10.1097\/QCO.0b013e3283165fd1","journal-title":"Curr Opin Infect Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705614","article-title":"Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy","volume":"39","author":"Trifilio SM","year":"2007","unstructured":"Trifilio SM, Bennett CL, Yarnold PR, et al.. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant. 2007, 39:425-9. 10.1038\/sj.bmt.1705614","journal-title":"Bone Marrow Transplant"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/myc.13335","article-title":"ECMM\/ISHAM recommendations for clinical management of COVID-19 associated mucormycosis in low- and middle-income countries","volume":"64","author":"Rudramurthy SM","year":"2021","unstructured":"Rudramurthy SM, Hoenigl M, Meis JF, et al.. ECMM\/ISHAM recommendations for clinical management of COVID-19 associated mucormycosis in low- and middle-income countries. Mycoses. 2021, 64:1028-37. 10.1111\/myc.13335","journal-title":"Mycoses"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30312-3","article-title":"Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium","volume":"19","author":"Cornely OA","year":"2019","unstructured":"Cornely OA, Alastruey-Izquierdo A, Arenz D, et al.. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019, 19:e405-21. 10.1016\/S1473-3099(19)30312-3","journal-title":"Lancet Infect Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/jim-2021-002179","article-title":"Utility of itraconazole and terbinafine in mucormycosis: a proof-of-concept analysis","volume":"70","author":"Gupta P","year":"2022","unstructured":"Gupta P, Malhotra HS, Saxena P, et al.. Utility of itraconazole and terbinafine in mucormycosis: a proof-of-concept analysis. J Investig Med. 2022, 70:914-8. 10.1136\/jim-2021-002179","journal-title":"J Investig Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.mmcr.2021.12.004","article-title":"Cryptococcus gattii meningitis complicated by immune reconstitution inflammatory syndrome in an apparent immunocompetent host in Malaysia","volume":"35","author":"Chang CY","year":"2022","unstructured":"Chang CY, Mohd Shah SH, Lio JY, Bahari N, Radhakrishnan AP. Cryptococcus gattii meningitis complicated by immune reconstitution inflammatory syndrome in an apparent immunocompetent host in Malaysia. Med Mycol Case Rep. 2022, 35:1-4. 10.1016\/j.mmcr.2021.12.004","journal-title":"Med Mycol Case Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/141776-successful-treatment-of-mucormycosis-caused-by-rhizopus-arrhizus-with-amphotericin-b-and-itraconazole","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:51:07Z","timestamp":1707508267000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/141776-successful-treatment-of-mucormycosis-caused-by-rhizopus-arrhizus-with-amphotericin-b-and-itraconazole"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,6]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.35814","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,6]]}}}